EP3139940A1 - Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation - Google Patents
Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulationInfo
- Publication number
- EP3139940A1 EP3139940A1 EP15736584.2A EP15736584A EP3139940A1 EP 3139940 A1 EP3139940 A1 EP 3139940A1 EP 15736584 A EP15736584 A EP 15736584A EP 3139940 A1 EP3139940 A1 EP 3139940A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- strain
- dsm
- mixture
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 30
- 208000030507 AIDS Diseases 0.000 title claims abstract description 12
- 208000032839 leukemia Diseases 0.000 title claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 title abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 4
- 230000009977 dual effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 88
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 36
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 24
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 230000001580 bacterial effect Effects 0.000 claims description 37
- 241000894006 Bacteria Species 0.000 claims description 20
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 19
- 239000011701 zinc Substances 0.000 claims description 19
- 229910052725 zinc Inorganic materials 0.000 claims description 19
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 12
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 11
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 9
- 241001116389 Aloe Species 0.000 claims description 8
- 240000007474 Aloe arborescens Species 0.000 claims description 8
- 235000004509 Aloe arborescens Nutrition 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 235000011399 aloe vera Nutrition 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 235000009569 green tea Nutrition 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 3
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 2
- 238000009630 liquid culture Methods 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 abstract description 36
- 108090000695 Cytokines Proteins 0.000 abstract description 36
- 210000004443 dendritic cell Anatomy 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 17
- 230000000770 proinflammatory effect Effects 0.000 abstract description 8
- 108010050904 Interferons Proteins 0.000 abstract description 6
- 102000014150 Interferons Human genes 0.000 abstract description 6
- 229940079322 interferon Drugs 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 46
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 34
- 230000000638 stimulation Effects 0.000 description 30
- 108010074328 Interferon-gamma Proteins 0.000 description 18
- 102100037850 Interferon gamma Human genes 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 210000000987 immune system Anatomy 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000002519 immonomodulatory effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 241001608472 Bifidobacterium longum Species 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 238000011360 adjunctive therapy Methods 0.000 description 4
- 229940009291 bifidobacterium longum Drugs 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000012200 cell viability kit Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101710121003 Oxygen-evolving enhancer protein 3, chloroplastic Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Definitions
- the present invention relates to a composition for human and animal use as a therapy for the treatment of tumors, acquired immunodeficiency syndrome and leukemias.
- the composition of the present invention for human and animal use as antitumor agent, comprises a mixture comprising or, preferably, consisting of a strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (Th1) interferon INF-gamma, said cytokines exhibit a marked antitumor activity, and/or a strain of bacteria Lactobacillus salivarius LS06 DSM 26037 which is able to strongly stimulate the production of dendritic cells, said dendritic cells also exhibit a marked antitumor activity.
- the current medical therapy is known to comprise chemotherapy, endocrine therapy, the treatment with immune response modifiers and the treatment with molecular-targeted drugs.
- the main purpose of antitumor chemotherapy is to kill, at any cell cycle phases, neoplastic cells and thus, reduce both primary tumor and metastasis masses.
- chemotherapy primarily affects the tumor but, unfortunately, it also causes side-effects on healthy tissues, specifically those with a fast proliferation and turnover, such as esophageal, gastric and intestinal mucosae, resulting in mucositis, nausea, vomiting, diarrhea, nutrient malabsorption and, thus, malnutrition.
- the common denominator of all chemotherapeutics is: bone marrow toxicity, which, in turn, leads to immunodepression and consequent infections, mainly caused by Gram-negative bacteria and fungi such as Candida, gastrointestinal epithelium toxicity and intestinal microflora toxicity (chemotherapeutic antibiotics).
- the Applicant found that the strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 shows a proven and surprising ability (see experimental part) to stimulate the production of pro-inflammatory cytokines (Th1) interferon I F-gamma.
- the strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 shows a surprising immunostimulatory activity towards the endogenous production of interferon gamma IFN- gamma.
- the strain of bacteria Lactobacillus reuteri LRE03 DSM 23879, selected by the Applicant exhibits a surprising immunomodulatory activity, since it activates the immune system through the stimulation of pro-inflammatory cytokines (Th1) interferon INF-gamma.
- the endogenous cytokine stimulation/production does not cause toxicity, as opposed to the infusion administration of said cytokines, as in the case of exogenous cytokines.
- the strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 is able to exert an effective antitumor action, by counteracting and reducing tumor cell proliferation.
- the Applicant also found that the strain of bacteria Lactobacillus salivarius LS06 DSM 26037 exhibits a proven and surprising ability (see experimental part) to stimulate the dendritic cell production. Dendritic cells assist the immune system in protecting organisms from outside attacks of dangerous microorganisms, such as viruses and bacteria.
- the strain of bacteria Lactobacillus salivarius LS06 DSM 26037 is able to exert an effective antitumor action, by counteracting and reducing tumor cell proliferation.
- said mixture (i) comprises or, alternatively, consists of:
- the (i) mixture of bacteria comprises or, alternatively, consists of:
- a strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 and a strain of bacteria Lactobacillus salivarius LS06 DSM 26037 in a weight ratio comprised from 1 :5 to 5:1 , preferably from 1 :3 to 3:1 , even more preferably from 1 :2 to 2:1 or 1 :1.
- the (i) mixture of bacteria has a bacterial cell concentration comprised from 1x10 s UFC/g of mixture to 1x10 12 UFC/g of mixture, preferably from 1x10 9 UFC/g of mixture to 1x10 11 UFC/g of mixture.
- bacterial cell concentration comprised from 1x10 s UFC/g of mixture to 1x10 12 UFC/g of mixture, preferably from 1x10 9 UFC/g of mixture to 1x10 11 UFC/g of mixture.
- compositions or compositions of the present invention comprises or, alternatively, consists of:
- a mixture comprising or, alternatively, consisting of a gum, preferably an alginate or a derivative thereof, and/or a gel, preferably an Aloe gel or a derivative thereof, and/or
- the composition of the present invention comprises or, alternatively, consists of: (i) a mixture of bacteria of the present invention and (iv) one or more food grade or pharma grade excipients and/or additives and/or co-formulants, acceptable by the body, said composition being for human and animal use in antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments.
- the composition of the present invention comprises or, alternatively, consists of: (i) a mixture of bacteria of the present invention, (ii) a mixture comprising or, alternatively, consisting of a gel, preferably an Aloe gel or a derivative thereof and (iv) one or more food grade or pharma grade excipients and/or additives and/or co-formulants, acceptable by the body, said composition being for human and animal use in antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments.
- Said (ii) mixture comprises or, alternatively, consists of a gel, preferably an Aloe gel or a derivative thereof.
- the Aloe product, or a derivative thereof is preferably Aloe arborescens; preferably in freeze-dried form. Aloe arborescens is preferably in freeze-dried form and exerts an anti-inflammatory action.
- the Applicant found that the immune system (IS) activation by the composition of the present invention takes place through a "dual biostimulation".
- the “dual biostimulation” consists of a first and a second biostimulations.
- the first biostimulation is obtained due to the presence, in the composition of the present invention, of very highly bioavailable zinc. This biologically available form of zinc stimulates the thymus to producing a greater amount (number) of lymphocytes. Said T-lymphocytes "overproduced” by the thymus produce non-toxic endogenous cytokines, such as interferon-gamma and dendritic cells.
- the second biostimulation is promoted by the strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 and/or the strain of bacteria Lactobacillus salivarius LS06 DSM 26037 which, in turn, stimulate lymphocytes, now in a greater amount due to the previous thymus stimulation by the zinc, to producing more cytokines (specifically, INF-gamma and dendritic cells).
- cytokines specifically, INF-gamma and dendritic cells.
- there is also a basal anti-inflammatory effect ensured by the presence of Aloe or a derivative thereof, preferably Aloe arborescens; preferably in freeze-dried form.
- the very high bioavailability of zinc derives from the fact that it is in the form of zinc internalized inside a tyndallized bacterial cell of a bacterial strain belonging to the species Bifidobacterium lactis, preferably the strain selected by the Applicant is the strain of bacteria Bifidobacterium lactis Bb 1 DSM 17850 deposited at DSMZ on 23.12.2005, being the object of the European Patent Application No. 08789404, herein incorporated by reference.
- the Applicant found that the highly bioavailable zinc internalized into a tyndallized cell (inactivated cell) is able to activate the immune system (IS), specifically the thymus responsible for the production of T-lymphocytes, which produce non-toxic endogenous cytokines, such as interferon-gamma and dendritic cells.
- IS immune system
- the composition of the present invention comprises or, alternatively, consists of: (i) a mixture of the present invention, (ii) a mixture comprising or, alternatively, consisting of a gel, preferably an Aloe gel or a derivative thereof, (iii) a source of highly assimilable and bioavailable zinc in the form of zinc internalized inside a tyndallized bacterial cell of a strain of bacteria belonging to the species Bifidobacterium lactis, preferably said strain is the strain of bacteria Bifidobacterium lactis Bb 1 DSM 17850 and (iv) one or more food grade or pharma grade additives and/or co-formulants and/or formulation technological ingredients, acceptable by the body, said composition being for human and animal use in antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments.
- Said (iv) source of highly assimilable and bioavailable zinc is present as organic zinc in the form of bacterial tyndallized product of the strain Bifidobacterium lactis Bb1 DSM 17850 (ProbioZinc®, deposited on 23.12.2005 at DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, by BioMan S.r.l. Company (Italy).
- the tyndallized bacterial product of the strain Bifidobacterium animalis ssp. lactis Bb1 DSM 17850 is in an amount comprised from 10 to 50 mg/g of composition, preferably 20 mg/g of composition.
- compositions of the present invention are effectively applicable for use as adjunctive therapy to antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments.
- composition of the present invention comprises food grade or pharma grade excipients and/or additives and/or co-formulants, which allow the manufacture of pharmaceutical forms as powders, granules, tablets or capsules. It can also contain, for example, fructooligosaccharides FOS and/or green tea and/or sucralose and/or maltodextrins.
- composition of the present invention comprises from 1x10 8 to 1X10 12 of viable bacterial cells UFC/g of composition, preferably from 1x10 9 to 1x10 11 of viable bacterial cells UFC/g of composition.
- the composition of the present invention is preferably recommended to be administered 1-2 times daily for 4- 12 weeks.
- the composition of the present invention comprises said Aloe, advantageously freeze-dried Aloe arborescens in an amount comprised from 1 to 25% by weight, relative to the weight of the composition; preferably from 5 to 15% by weight, relative to the weight of the composition.
- the composition of the present invention may contain freeze-dried Aloe arborescens (AlagelTM) for example 1 ,5 gram/dose.
- AlagelTM freeze-dried Aloe arborescens
- the composition of the present invention is able to make the side effects of a chemotherapeutic treatment more tolerable in individuals with a tumor disease.
- the composition of the present invention comprises the (i) mixture of the present invention (having a bacterial cell concentration comprised from 1x10 8 UFC/g of mixture to 1x10 12 UFC/g of mixture, preferably from 1x10 9 UFC/g of mixture to 1x10 11 UFC/g of mixture) comprising or, alternatively, consisting of:
- a strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 and a strain of bacteria Lactobacillus salivarius LS06 DSM 26037 in a weight ratio comprised from 1 :5 to 5:1 , preferably from 1 :3 to 3:1 , even more preferably from 1 :2 to 2:1 or 1 :1 , and/or fructooligosaccharides FOS and/or green tea and/or sucralose and/or maltodextrins.
- the strain L. reuteri LRE03 DSM 23879 is able to significantly stimulate the endogenous production of interferon-gamma (IFN- ⁇ ).
- IFN- ⁇ interferon-gamma
- the ability of the strain L reuteri LRE03 DSM 23879 to induce the release of cytokines, in particular interferon-gamma INF-gamma, by the primary cells of immune system was quantified by co-incubation thereof with PBMCs (Peripheral Blood Mononuclear Cells) isolated from peripheral blood of healthy adult individuals. The results showed a stimulation of IFN-gamma secretion with a concentration of 480 pg/ml, namely 47-fold greater than the control.
- PBMCs Peripheral Blood Mononuclear Cells
- IFN-gamma production was assessed in the culture supernatant after 5 days of stimulation relative to non-stimulation conditions (baseline).
- Interferon-gamma IFN- ⁇
- IFN- ⁇ Interferon-gamma
- IFN- Y also shows a pivotal and characteristic immunomodulatory effect, by stimulating the activity of both cells specialized in the body's immune response such as macrophages, monocytes, neutrophils and unspecialized cells such as platelets, endothelial and epithelial cells, fibroblasts and parenchymal cells.
- the composition of the present invention ensures a suitable amount (2 mg/dose) of highly assimilable zinc internalized by the microorganism Bifidobacterium lactis Bbl
- the highly bioavailable (internalized) zinc is in the form of a tyndallized (inactivated) cell. This form of zinc is very bioavailable and, thus, more easily assimilable by the organism.
- the zinc ion being bioavailable and readily assimilable by the organism, plays a pivotal role and a direct action towards the thymus, which is responsible for the stimulation/production of lymphocytes, which produce more cytokines.
- the strain of bacteria Bifidobacterium lactis Bb 1 DSM 17850 was deposited at DSMZ on 23.12.2005, by BioMan S.r.l. Company (Italy). Indeed, the strain of bacteria Bifidobacterium lactis Bb 1 DSM 17850 is able to accumulate zinc inside the cell during its growth in a liquid culture medium.
- the dietary zinc accumulated inside the cell (ProbioZinc®) has an assimilability 17-fold greater than zinc gluconate and 31.5-fold greater than zinc sulfate, as shown in an in vitro study carried out on Caco-2 cells in a Transwell system.
- the high assimilability of the trace element zinc allows to effectively counterbalancing deficiency conditions even at very low dosages.
- composition being object of the present invention is effectively applied for use as adjunctive therapy in individuals with tumor diseases and undergoing chemotherapy, as well as in antiretroviral treatments in individuals with Acquired Immunodeficiency Syndrome (AIDS) and leukemia treatments.
- AIDS Acquired Immunodeficiency Syndrome
- the Applicant tested the immunomodulatory properties of the strain of bacteria Lactobacillus reuteri LRE 03 (ID1777) DSM 23879, as described below.
- bacterial cultures of the strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 were prepared under specific growth conditions.
- the strain was cultured in Man Rogosa Sharpe (MRS) medium, in a thermostatic bath at 37°C.
- MRS Man Rogosa Sharpe
- immunomodulatory experiments after a growth period of approximately 16 hours, bacteria were subcultured for 6 hours, under the above-cited conditions, in order to reach the exponential growth phase.
- peripheral blood mononuclear cells were separated.
- the peripheral blood mononuclear cells (PBMC) were separated by density gradient centrifugation.
- 20 ml of "buffy coat' of healthy donors from the Immuno-transfusion Service of Ospedale di Borgomanero (Italy) were used for each experiment, thus obtaining an average yield of 200x10 6 PBMCIbuffy.
- the amount of separated cells was determined by cell count in Burker's chambers, using Turk's dye, which allows to discriminating between mononuclear and polymorphonuclear cells.
- Cells were brought to a concentration of 2x10 6 cells/ml in RPMI-1640 growth medium (Invitrogen), supplemented with 10% heat inactivated Bovine fetal serum (FCS, Gibco), 1% glutamine and 25 mM Hepes.
- RPMI-1640 growth medium Invitrogen
- FCS Bovine fetal serum
- PBMC peripheral blood mononuclear cells
- PBMCs stimulated with 1 pg/ml Lipopolysaccharide (LPS; Escherichia coli, serotype 055:B5, Sigma Chemicals Co., St. Louis, MO).
- LPS Lipopolysaccharide
- PBMCs stimulated with 1 g/ml Phytohaemagglutinin (PHA-P; Sigma Chemicals Co., St. Louis, MO).
- PHA-P Phytohaemagglutinin
- the cellular DNA was labeled with anti-Brdll FITC-conjugated monoclonal antibody (mAb) ⁇ Becton Dickinson).
- mAb monoclonal antibody
- the cells were analyzed within 24 hours from their preparation by using a cytofluorimeter FACScalibur from Becton Dikinson Company and the analysis program CellQuest.
- Results were expressed as cell proliferation index (P. I.), being calculated as ratio of the percentage of proliferating cells in the presence of stimulus and the percentage of the same in the absence of stimulation. A P.I. value greater than 2 was considered acceptable (cut-off value). In all the experiments, stimulation with the mitogen (PHA) as control always resulted greater than the cut-off value, confirming that PBMCs were viable and with proliferative capability. e) Analysis of molecules characterizing individual cell subpopulations
- Cytokine concentration in the culture supernatants was determined by E.L.I.S.A. assay (Enzyme-Linked Immunoabsorbent Assay). Specifically, for cytokine (IL-4, IL-10, IFN-Y and IL-12p70) dosage, the kits "Human ELISA Ready-SET-Go" from eBioscence Company, San Diego CA were used. g) Statistical analysis
- PBMC peripheral blood mononuclear cells
- PHA Phytohaemagglutinin
- T-lymphocytes represent the main effector and regulatory cells of cell-mediate immunity.
- T-cells synthetize and secrete a variety of cytokines required for growth and differentiation and as activating factors of other immunocompetent cells.
- PBMCs peripheral blood mononuclear cells
- cytokines IL-12p70, IFN- ⁇ and IL-4
- the amount of cytokines (IL-12p70, IFN- ⁇ and IL-4) being released in the culture supernatants was measured by E.L.I.S.A. assay.
- Cytokines with predominantly pro-inflammatory action The induction of cytokines IL-12p70 and IFN- ⁇ , as main representatives of cytokines with predominantly pro-inflammatory action was assessed. As shown in figure 4, the bacterial strain Lactobacillus reuteri LRE 03 (DSM 23879) is able to induce a significant increase of both the tested cytokines, relative to basal conditions.
- Cytokines with predominantly immunoregulatory action is assessed.
- cytokines IL-4 as main representatives of cytokines with predominantly immunoregulatory action was assessed.
- the tested bacterial strain Lactobacillus reuteri LRE 03 shown to be able to induce a reduction of cytokine IL-4 secretion, relative to basal conditions.
- the bacterial strain Lactobacillus reuteri LRE 03 (DSM 23879) resulted the best IFN- ⁇ inducing agent relative to both strains of the same species and strains of different species, all belonging to the genus Lactobacillus.
- the Applicant tested the immunomodulatory properties of the bacterial strain Lactobacillus salivarius LS 06 DSM 26037, as described below.
- the strain was cultured in Man Rogosa Sharpe (MRS) medium, in a thermostatic bath at 37°C.
- MRS Man Rogosa Sharpe
- the bacteria were subcultured for 6 hours, under the above-cited conditions, in order to reach the exponential growth phase.
- PBS sterile phosphate-buffered saline
- the physiological status and the number of cells were determined with a cytofluorimetric technique by using the commercial kit "Cell Viability Kit with liquid beads", marketed by Becton Dickinson Company, following the manufacturer's instructions.
- the cells were then brought to the optimal concentration established in preliminary experiments and used in subsequent tests.
- PBMC Peripheral blood mononuclear cells
- 20 ml of "buffy coat" of healthy donors from the Immuno-transfusion Service of Ospedale di Borgomanero were used for each experiment, thereby obtaining an average yield of 200 x 10 6 PBMC/buffy.
- the amount of separated cells was determined by cell count in Burker's chambers, by using Turk's dye, which allows to discriminating between mononuclear cells and polymorphonuclear cells.
- the cells were brought to a concentration of 2 x 10 6 cells/ml in RPMI-1640 growth medium (Invitrogen), supplemented with 10% heat inactivated Bovine fetal serum (FCS, Gibco), 1% glutamine and 25 mM Hepes.
- FCS Bovine fetal serum
- PBMCs were stimulated for 24 hours with the bacterial strain.
- the internal controls for each experiment were as follows: Negative control: PBMCs alone; 1 day control: PBMCs stimulated with 1 pg/ml Lipopolysaccharide (LPS; Escherichia coli, serotype 055.B5, Sigma Chemicals Co., St. Louis, MO).
- LPS Lipopolysaccharide
- the cultures were centrifuged at 1500 rpm for 10 minutes. Then the supernatant was discharged and the cells used for subsequent tests.
- mAb monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC) or peridinin chlorophyll protein (PerCP): CD3, CD14, CD16, CD19, CD20, CD56 and HLA-DR.
- FITC fluorescein isothiocyanate
- PerCP peridinin chlorophyll protein
- the bacterial strain L salivarius LS 06 (DSM 26037) increased by 7-fold the percentage of total dendritic cells, relative to non-stimulation conditions (baseline, figure 6B).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition for human and animal use as a therapy for the treatment of tumors, acquired immunodeficiency syndrome and leukemias. The composition of the present invention, for human and animal use as antitumor agent, consists of a mixture comprising or, preferably, consisting of a strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (Th1) interferon INF-gamma, said cytokines exhibit a marked antitumor activity, and/or a strain of bacteria Lactobacillus salivarius LS06 DSM 26037 which is able to strongly stimulate the production of dendritic cells, said dendritic cells also exhibit a marked antitumor activity.
Description
DESCRIPTION of the invention entitled: "Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation"
The present invention relates to a composition for human and animal use as a therapy for the treatment of tumors, acquired immunodeficiency syndrome and leukemias. The composition of the present invention, for human and animal use as antitumor agent, comprises a mixture comprising or, preferably, consisting of a strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (Th1) interferon INF-gamma, said cytokines exhibit a marked antitumor activity, and/or a strain of bacteria Lactobacillus salivarius LS06 DSM 26037 which is able to strongly stimulate the production of dendritic cells, said dendritic cells also exhibit a marked antitumor activity.
As regards oncology, the current medical therapy is known to comprise chemotherapy, endocrine therapy, the treatment with immune response modifiers and the treatment with molecular-targeted drugs. The main purpose of antitumor chemotherapy is to kill, at any cell cycle phases, neoplastic cells and thus, reduce both primary tumor and metastasis masses.
It is known that antitumor chemotherapeutic treatments decrease the immune system activity and that a compromised immune system is unable to protect organisms against viral and bacterial infections.
In addition, it is known that chemotherapy (chemo) primarily affects the tumor but, unfortunately, it also causes side-effects on healthy tissues, specifically those with a fast proliferation and turnover, such as esophageal, gastric and intestinal mucosae, resulting in mucositis, nausea, vomiting, diarrhea, nutrient malabsorption and, thus, malnutrition.
Therefore, the common denominator of all chemotherapeutics is: bone marrow toxicity, which, in turn, leads to immunodepression and consequent infections, mainly caused by Gram-negative bacteria and fungi such as Candida, gastrointestinal epithelium toxicity and intestinal microflora toxicity (chemotherapeutic antibiotics).
Accordingly, it would be desirable to have a natural, effective and well-tolerated composition so that to lessen the adverse effects, typical of a chemotherapeutic treatment.
Thus, there is still a strong need for having an adjunctive therapy in order to prevent and/or reduce both symptoms and side effects of chemotherapy being used for the treatment of tumors.
Furthermore, there is still a need for having an adjunctive therapy to chemotherapy, being able to act on immune system by stimulating it (immunostimulation), in order to restore its efficacy, since chemotherapy is well known to entail a reduction of the immune system efficacy.
After a long and intensive research and development activity on a wide group of bacterial strains belonging to different species, the Applicant identified and selected specific bacterial strains, which suitably meet the above-cited needs.
It is an object of the present invention:
- a strain of bacteria belonging to the species Lactobacillus reuteri identified as Lactobacillus reuteri LRE03 with deposit number DSM 23879, deposited on 05.08.2010 by Probiotical SpA at DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, under the Budapest Treaty, and/or
- a strain of bacteria belonging to the species Lactobacillus salivarius identified as Lactobacillus salivarius LS06 with deposit number DSM 26037, deposited on 06.06.2012 by Probiotical SpA at DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, under the Budapest Treaty.
The Applicant found that the strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 shows a proven and surprising ability (see experimental part) to stimulate the production of pro-inflammatory cytokines (Th1) interferon I F-gamma. The strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 shows a surprising immunostimulatory activity towards the endogenous production of interferon gamma IFN- gamma. The strain of bacteria Lactobacillus reuteri LRE03 DSM 23879, selected by the Applicant, exhibits a surprising immunomodulatory activity, since it activates the immune system through the stimulation of pro-inflammatory cytokines (Th1) interferon INF-gamma. The endogenous cytokine stimulation/production does not cause toxicity, as opposed to the infusion administration of said cytokines, as in the case of exogenous cytokines.
By virtue of the strong stimulation of the production of pro-inflammatory cytokines (Th1) interferon INF- gamma, the strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 is able to exert an effective antitumor action, by counteracting and reducing tumor cell proliferation.
The Applicant also found that the strain of bacteria Lactobacillus salivarius LS06 DSM 26037 exhibits a proven and surprising ability (see experimental part) to stimulate the dendritic cell production. Dendritic cells assist the immune system in protecting organisms from outside attacks of dangerous microorganisms, such as viruses and bacteria.
Because of its strong stimulation of dendritic cell production, the strain of bacteria Lactobacillus salivarius LS06 DSM 26037 is able to exert an effective antitumor action, by counteracting and reducing tumor cell proliferation.
It is an object of the present invention a (i) mixture of bacteria comprising or, alternatively, consisting of: a strain of bacteria Lactobacillus reuteri LRE03 DSM 23879, and/or a strain of bacteria Lactobacillus salivarius LS06 DSM 26037, for human or animal use as antitumor agent.
In an embodiment, said mixture (i) comprises or, alternatively, consists of:
- a strain of bacteria Lactobacillus reuteri LRE03 DSM 23879, and/or
- a strain of bacteria Lactobacillus salivarius LS06 DSM 26037,
for human or animal use in tumor treatment for counteracting and/or reducing tumor cell proliferation, in acquired immunodeficiency syndrome treatment and leukemia treatment.
In another embodiment, the (i) mixture of bacteria comprises or, alternatively, consists of:
- a strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 and a strain of bacteria Lactobacillus salivarius LS06 DSM 26037, in a weight ratio comprised from 1 :5 to 5:1 , preferably from 1 :3 to 3:1 , even more preferably from 1 :2 to 2:1 or 1 :1.
The (i) mixture of bacteria has a bacterial cell concentration comprised from 1x10s UFC/g of mixture to 1x1012 UFC/g of mixture, preferably from 1x109 UFC/g of mixture to 1x1011 UFC/g of mixture. Within the context of the present invention, all the above-cited mixtures are referred to, for the sake of brevity, as "the mixture of bacteria or the mixtures of bacteria of the present invention".
It is another object of the present invention a pharmaceutical composition or a medical device composition, which is meant as a substance in compliance with the directive 93/42/EEC definition, hereinafter referred to, for the sake of brevity, as "the composition or compositions of the present invention", said composition comprises or, alternatively, consists of:
(i) a mixture of bacteria of the present invention, as described above, and/or
(ii) a mixture comprising or, alternatively, consisting of a gum, preferably an alginate or a derivative thereof, and/or a gel, preferably an Aloe gel or a derivative thereof, and/or
(iii) a source of highly assimilable zinc, and/or
(iv) one or more food grade or pharma grade excipients and/or additives and/or co-formulants, acceptable by the body, such as preferably fructooligosaccharides (FOS), green tea, sucralose and/or maltodextrins. In an embodiment, which is an object of the present invention, the composition of the present invention comprises or, alternatively, consists of: (i) a mixture of bacteria of the present invention and (iv) one or more food grade or pharma grade excipients and/or additives and/or co-formulants, acceptable by the body, said composition being for human and animal use in antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments.
In another embodiment, which is an object of the present invention, the composition of the present invention comprises or, alternatively, consists of: (i) a mixture of bacteria of the present invention, (ii) a mixture comprising or, alternatively, consisting of a gel, preferably an Aloe gel or a derivative thereof and (iv) one or more food grade or pharma grade excipients and/or additives and/or co-formulants, acceptable by the body, said composition being for human and animal use in antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments. Said (ii) mixture comprises or, alternatively, consists of a gel, preferably an Aloe gel or a derivative thereof. The Aloe product, or a derivative thereof, is preferably Aloe arborescens; preferably in freeze-dried form. Aloe arborescens is preferably in freeze-dried form and exerts an anti-inflammatory action.
Furthermore, the Applicant found that the immune system (IS) activation by the composition of the present invention takes place through a "dual biostimulation". The "dual biostimulation" consists of a first and a
second biostimulations. The first biostimulation is obtained due to the presence, in the composition of the present invention, of very highly bioavailable zinc. This biologically available form of zinc stimulates the thymus to producing a greater amount (number) of lymphocytes. Said T-lymphocytes "overproduced" by the thymus produce non-toxic endogenous cytokines, such as interferon-gamma and dendritic cells. The second biostimulation, combined with the first one, is promoted by the strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 and/or the strain of bacteria Lactobacillus salivarius LS06 DSM 26037 which, in turn, stimulate lymphocytes, now in a greater amount due to the previous thymus stimulation by the zinc, to producing more cytokines (specifically, INF-gamma and dendritic cells). In addition to the above, there is also a basal anti-inflammatory effect ensured by the presence of Aloe or a derivative thereof, preferably Aloe arborescens; preferably in freeze-dried form.
The very high bioavailability of zinc derives from the fact that it is in the form of zinc internalized inside a tyndallized bacterial cell of a bacterial strain belonging to the species Bifidobacterium lactis, preferably the strain selected by the Applicant is the strain of bacteria Bifidobacterium lactis Bb 1 DSM 17850 deposited at DSMZ on 23.12.2005, being the object of the European Patent Application No. 08789404, herein incorporated by reference.
Basically, the Applicant found that the highly bioavailable zinc internalized into a tyndallized cell (inactivated cell) is able to activate the immune system (IS), specifically the thymus responsible for the production of T-lymphocytes, which produce non-toxic endogenous cytokines, such as interferon-gamma and dendritic cells.
In another embodiment, which is an object of the present invention, the composition of the present invention comprises or, alternatively, consists of: (i) a mixture of the present invention, (ii) a mixture comprising or, alternatively, consisting of a gel, preferably an Aloe gel or a derivative thereof, (iii) a source of highly assimilable and bioavailable zinc in the form of zinc internalized inside a tyndallized bacterial cell of a strain of bacteria belonging to the species Bifidobacterium lactis, preferably said strain is the strain of bacteria Bifidobacterium lactis Bb 1 DSM 17850 and (iv) one or more food grade or pharma grade additives and/or co-formulants and/or formulation technological ingredients, acceptable by the body, said composition being for human and animal use in antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments. Said (iv) source of highly assimilable and bioavailable zinc is present as organic zinc in the form of bacterial tyndallized product of the strain Bifidobacterium lactis Bb1 DSM 17850 (ProbioZinc®, deposited on 23.12.2005 at DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, by BioMan S.r.l. Company (Italy). The tyndallized bacterial product of the strain Bifidobacterium animalis ssp. lactis Bb1 DSM 17850 is in an amount comprised from 10 to 50 mg/g of composition, preferably 20 mg/g of composition.
All the above-cited compositions of the present invention are effectively applicable for use as adjunctive therapy to antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments.
Finally, the composition of the present invention comprises food grade or pharma grade excipients and/or additives and/or co-formulants, which allow the manufacture of pharmaceutical forms as powders, granules, tablets or capsules. It can also contain, for example, fructooligosaccharides FOS and/or green tea and/or sucralose and/or maltodextrins.
The composition of the present invention comprises from 1x108 to 1X1012 of viable bacterial cells UFC/g of composition, preferably from 1x109 to 1x1011 of viable bacterial cells UFC/g of composition. The composition of the present invention is preferably recommended to be administered 1-2 times daily for 4- 12 weeks.
The composition of the present invention comprises said Aloe, advantageously freeze-dried Aloe arborescens in an amount comprised from 1 to 25% by weight, relative to the weight of the composition; preferably from 5 to 15% by weight, relative to the weight of the composition. The composition of the present invention may contain freeze-dried Aloe arborescens (Alagel™) for example 1 ,5 gram/dose. In light of its overall mechanism of action, the composition of the present invention is able to make the side effects of a chemotherapeutic treatment more tolerable in individuals with a tumor disease.
In an embodiment, the composition of the present invention comprises the (i) mixture of the present invention (having a bacterial cell concentration comprised from 1x108 UFC/g of mixture to 1x1012 UFC/g of mixture, preferably from 1x109 UFC/g of mixture to 1x1011 UFC/g of mixture) comprising or, alternatively, consisting of:
- a strain of bacteria Lactobacillus reuteri LRE03 DSM 23879, or
- a strain of bacteria Lactobacillus salivarius LS06 DSM 26037, or
- a strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 and a strain of bacteria Lactobacillus salivarius LS06 DSM 26037, in a weight ratio comprised from 1 :5 to 5:1 , preferably from 1 :3 to 3:1 , even more preferably from 1 :2 to 2:1 or 1 :1 , and/or fructooligosaccharides FOS and/or green tea and/or sucralose and/or maltodextrins.
Indeed, the strain L. reuteri LRE03 DSM 23879 is able to significantly stimulate the endogenous production of interferon-gamma (IFN-γ). The ability of the strain L reuteri LRE03 DSM 23879 to induce the release of cytokines, in particular interferon-gamma INF-gamma, by the primary cells of immune system was quantified by co-incubation thereof with PBMCs (Peripheral Blood Mononuclear Cells) isolated from peripheral blood of healthy adult individuals. The results showed a stimulation of IFN-gamma secretion with a concentration of 480 pg/ml, namely 47-fold greater than the control. The IFN-gamma production was assessed in the culture supernatant after 5 days of stimulation relative to non-stimulation conditions (baseline). Interferon-gamma (IFN-γ) has hindrance properties against viral and bacterial infections, similarly to the other interferons, and non-physiological cell proliferation, which is mediated by changes of cytoskeleton and cell membrane, modulations of oncogene product expression and regulation of the cell differentiation process (protraction of almost all the phases of mitosis both in normal and tumor cells). IFN- Y also shows a pivotal and characteristic immunomodulatory effect, by stimulating the activity of both cells
specialized in the body's immune response such as macrophages, monocytes, neutrophils and unspecialized cells such as platelets, endothelial and epithelial cells, fibroblasts and parenchymal cells. The composition of the present invention ensures a suitable amount (2 mg/dose) of highly assimilable zinc internalized by the microorganism Bifidobacterium lactis Bbl The highly bioavailable (internalized) zinc is in the form of a tyndallized (inactivated) cell. This form of zinc is very bioavailable and, thus, more easily assimilable by the organism. The zinc ion, being bioavailable and readily assimilable by the organism, plays a pivotal role and a direct action towards the thymus, which is responsible for the stimulation/production of lymphocytes, which produce more cytokines.
The strain of bacteria Bifidobacterium lactis Bb 1 DSM 17850 was deposited at DSMZ on 23.12.2005, by BioMan S.r.l. Company (Italy). Indeed, the strain of bacteria Bifidobacterium lactis Bb 1 DSM 17850 is able to accumulate zinc inside the cell during its growth in a liquid culture medium. The dietary zinc accumulated inside the cell (ProbioZinc®) has an assimilability 17-fold greater than zinc gluconate and 31.5-fold greater than zinc sulfate, as shown in an in vitro study carried out on Caco-2 cells in a Transwell system. The high assimilability of the trace element zinc allows to effectively counterbalancing deficiency conditions even at very low dosages. Furthermore, zinc is known for playing an important role on the immune system, specially the thymus, the organ where the production of T-lymphocytes takes place which, when differentiate to CD4+ T-lymphocytes (helper T-lymphocytes), secrete a series of cytokines such as IL-12 and IFN-γ. Said zinc mechanism of action is synergistic with that of the strain L reuteri LRE03 DSM 23879.
In light of its overall mechanism of action, the composition being object of the present invention is effectively applied for use as adjunctive therapy in individuals with tumor diseases and undergoing chemotherapy, as well as in antiretroviral treatments in individuals with Acquired Immunodeficiency Syndrome (AIDS) and leukemia treatments.
Experimental part
The Applicant tested the immunomodulatory properties of the strain of bacteria Lactobacillus reuteri LRE 03 (ID1777) DSM 23879, as described below.
Specifically, the investigation was conducted after different times of stimulation, so that to analyze both cytokines involved in innate immunity and those responsible for acquired immunity. a) Bacterial cultures and growth conditions
Firstly, bacterial cultures of the strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 were prepared under specific growth conditions. The strain was cultured in Man Rogosa Sharpe (MRS) medium, in a
thermostatic bath at 37°C. As regards the immunomodulatory experiments, after a growth period of approximately 16 hours, bacteria were subcultured for 6 hours, under the above-cited conditions, in order to reach the exponential growth phase. Then, they were washed twice with sterile phosphate-buffered saline (PBS, pH 7.2); the physiological status and the number of cells were determined with a cytofluorimetric technique by using the commercial kit "Cell Viability Kit with liquid beads", marketed by Becton Dickinson Company, following the manufacturer's instructions. The cells were thus brought to the optimal concentration established in preliminary experiments and used in subsequent tests. b) Peripheral blood mononuclear cell separation
Next, peripheral blood mononuclear cells were separated. The peripheral blood mononuclear cells (PBMC) were separated by density gradient centrifugation. For this aim, 20 ml of "buffy coat' of healthy donors from the Immuno-transfusion Service of Ospedale di Borgomanero (Italy) were used for each experiment, thus obtaining an average yield of 200x106 PBMCIbuffy. The amount of separated cells was determined by cell count in Burker's chambers, using Turk's dye, which allows to discriminating between mononuclear and polymorphonuclear cells. Cells were brought to a concentration of 2x106 cells/ml in RPMI-1640 growth medium (Invitrogen), supplemented with 10% heat inactivated Bovine fetal serum (FCS, Gibco), 1% glutamine and 25 mM Hepes.
c) PBMC stimulation
Next, the peripheral blood mononuclear cells (PBMC) were stimulated with the bacterial strain. After separation, PBMCs were stimulated with the bacterial strain for 1 and 5 days. The internal controls for each experiment were as follows:
Negative control: PBMCs alone
1 day control: PBMCs stimulated with 1 pg/ml Lipopolysaccharide (LPS; Escherichia coli, serotype 055:B5, Sigma Chemicals Co., St. Louis, MO).
5 days control: PBMCs stimulated with 1 g/ml Phytohaemagglutinin (PHA-P; Sigma Chemicals Co., St. Louis, MO).
At the different times of analysis, cultures were centrifuged at 1500 rpm for 10 minutes. Supernatants were taken and stored at -20°C until analysis. The cells were used for subsequent tests. d) Cell proliferation analysis
Then, the cell proliferation analysis was performed. Cell proliferation was assessed with a cytofluorimetric technique by using the bromodeoxyuridine (BrdU) nuclear labeling protocol. This method was developed as alternative to the more traditional radiolabeling system with tritiated thymidine. Particularly, cell cultures were added with a mixture of 5-bromo-2'-deoxyuridine (BrdU) and 2'-deoxycytidine (dC), either at 20 μΜ final concentration. Following to 16-hour incubation at 37°C under humidified atmosphere, 5% CO2, the cell proliferation was analyzed by a cytofluorimetric technique. The culture supernatants were harvested and stored at -20°C until analysis. Following to fixation and cell wall permeabilization, the cellular DNA was labeled with anti-Brdll FITC-conjugated monoclonal antibody (mAb) {Becton Dickinson). The cells were analyzed within 24 hours from their preparation by using a cytofluorimeter FACScalibur from Becton Dikinson Company and the analysis program CellQuest.
Results were expressed as cell proliferation index (P. I.), being calculated as ratio of the percentage of proliferating cells in the presence of stimulus and the percentage of the same in the absence of stimulation. A P.I. value greater than 2 was considered acceptable (cut-off value). In all the experiments, stimulation with the mitogen (PHA) as control always resulted greater than the cut-off value, confirming that PBMCs were viable and with proliferative capability.
e) Analysis of molecules characterizing individual cell subpopulations
Next, the analyses of molecules characterizing the individual cell subpopulations were performed. As regards the immunophenotypic characterization, the cells were incubated for 30 minutes in the dark, with different combinations of the following monoclonal antibodies (mAb) conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE) or peridinin chlorophyll protein (PerCP): CD3, CD4, CD8, CD14, CD16, CD19, CD20, CD56, HLA-DR. After incubation, the samples were washed, fixed with a solution containing 1% paraformaldehyde and stored at 4°C. Within 24 hours from preparation, the samples were analyzed by a cytofluorimeter FACScalibur, the cells being selected so that to exclude contaminant cellular debris from analysis. f) Cytokine dosage
Next, the cytokine dosage was performed. Cytokine concentration in the culture supernatants was determined by E.L.I.S.A. assay (Enzyme-Linked Immunoabsorbent Assay). Specifically, for cytokine (IL-4, IL-10, IFN-Y and IL-12p70) dosage, the kits "Human ELISA Ready-SET-Go" from eBioscence Company, San Diego CA were used. g) Statistical analysis
A statistical analysis by using the paired Student's t test was performed. A p<0.05 value was considered significant.
RESULTS i) The proliferative response induced by the strain of bacteria Lactobacillus reuteri LRE 03 DSM 23879 was determined. In vitro analysis of cell proliferation is a very useful biological parameter for investigating the immune system functioning. In order to analyze whether the tested bacterial strain could affect the induction of lymphocyte proliferation, peripheral blood mononuclear cells (PBMC) were stimulated with the bacterial strain Lactobacillus reuteri LRE 03 DSM 23879. Phytohaemagglutinin (PHA), which is a mitogenic stimulus able to induce T-lymphocyte polyclonal proliferation, was used as positive control. PBMCs were separated from peripheral venous blood samples of 4 healthy male donors, average age of 40 years (range 21-52 years), from the Transfusion Service of Ospedale S.S. Trinita, Borgomanero (Novara).
As shown in figure 1 , where the cell proliferation index (P.I., see the above-described methods) is reported, the PBMC proliferative response under all the stimulation conditions resulted significantly higher than in absence of stimulation (baseline).
In figure 1 , the Mean ± standard error of the mean (S.E.M.) of 4 independent experiments is shown. The statistical significance was calculated by using the Student's f test, p < 0.05 values have to be considered statistically significant, as compared to the baseline (non-stimulated PBMCs). ii) The effects of the bacterial strain Lactobacillus reuteri LRE 03 DSM 23879 on the different cell subpopulations were assessed. In order to detect which cell subpopulations were induced to proliferate following to stimulation with the tested probiotic strain, a multiparametric flow cytometry analysis was performed. The subsequent figures (Figure 2 and Figure 3) show the percentage of the main cell subpopulations involved both in natural and acquired immune response. iia) Natural Immunity. After one day, the stimulation with the bacterial strain Lactobacillus reuteri LRE 03 (DSM 23879) caused a change in total dendritic cell (Lineage-/HLA-DR+) percentage.
In figure 2, the proliferative response Mean ± S.E.M. of 4 independent experiments is shown. The statistical significance was calculated by using the Student's f test, p < 0.05 values have to be considered statistically significant, as compared to the baseline (non-stimulated PBMCs). iib) Acquired Immunity. After five days, the stimulation with the bacterial strain Lactobacillus reuteri LRE 03 DSM 23879 caused a significant increase in helper T-lymphocytes (CD3+/CD4) percentage.
In figure 3, the Mean ± S.E.M. of 12 independent experiments is shown. The statistical significance was calculated by using the Student's t test, p < 0.05 values have to be considered statistically significant, as compared to the basal condition (non-stimulated PBMCs).
Hi) Cytokine secretion. The different spectrum of cytokines secreted by cell subpopulations involved in immune responses plays a pivotal role in selecting the effector system to be used in response to a specific antigenic stimulus. T-lymphocytes represent the main effector and regulatory cells of cell-mediate immunity. In response to an antigen or pathogenic agent, T-cells synthetize and secrete a variety of cytokines required for growth and differentiation and as activating factors of other immunocompetent cells. In order to investigate whether the tested bacterial strain would induce a different cytokine secretion by PBMCs, said cells were activated for 1 and 5 days. The amount of cytokines (IL-12p70, IFN-γ and IL-4) being released in the culture supernatants was measured by E.L.I.S.A. assay. iv) Cytokines with predominantly pro-inflammatory action. The induction of cytokines IL-12p70 and IFN-γ, as main representatives of cytokines with predominantly pro-inflammatory action was assessed. As shown in figure 4, the bacterial strain Lactobacillus reuteri LRE 03 (DSM 23879) is able to induce a significant increase of both the tested cytokines, relative to basal conditions. v) Cytokines with predominantly immunoregulatory action. The induction of cytokines IL-4, as main representatives of cytokines with predominantly immunoregulatory action was assessed. As shown in
figure 4, the tested bacterial strain Lactobacillus reuteri LRE 03 (DSM 23879) shown to be able to induce a reduction of cytokine IL-4 secretion, relative to basal conditions.
In figure 4 the Mean ± S.E.M. of 4 independent experiments is shown. The statistical significance was calculated by using the Student's t test, p < 0.05 values have to be considered statistically significant, as compared to the baseline (non-stimulated PBMCs). The production of cytokines IL-12p70 was assessed in culture supernatants after 1 day of stimulation. IFN-y and IL-4 production was assessed in culture supernatants after 5 days of stimulation.
Data relative to the dosage of cytokines secreted by PBMCs following to stimulation with the bacterial strain Lactobacillus reuteri LRE 03 DSM 23879 underlined the capability of the strain itself to significantly increase pro-inflammatory cytokines. Specifically, the bacterial strain Lactobacillus reuteri LRE 03 DSM 23879 increased by 6-fold and 47-fold the secretion of cytokine IL-12p70 and cytokine IFN-γ, respectively, relative to non-stimulation conditions (baseline, figure 5).
Considering the marked ability of the bacterial strain Lactobacillus reuteri LRE 03 DSM 23879 to stimulate the cytokine IFN-γ secretion, the results of the present study were compared to those obtained from experiments with other bacterial strains, all belonging to Probiotical S.p.A. collection. Specifically, the increase relative to the baseline was compared, namely the fold change of the IFN-γ amount, relative to non-stimulation conditions (baseline).
As shown in table 1 , the bacterial strain Lactobacillus reuteri LRE 03 (DSM 23879) resulted the best IFN-γ inducing agent relative to both strains of the same species and strains of different species, all belonging to the genus Lactobacillus.
In Table 1 , the increase of cytokine IFN-γ induced by stimulation with different lactobacilli and bifidobacteria, compared to the baseline, is shown.
Experimental part
The Applicant tested the immunomodulatory properties of the bacterial strain Lactobacillus salivarius LS 06 DSM 26037, as described below.
Specifically, the immunomodulatory properties towards total circulating dendritic cells of the probiotic strain Lactobacillus salivarius LS 06 DSM 26037, previously characterized from both the microbiological and molecular point of views, were assessed. In particular, after 24 hours of stimulation, a multiparametric flow cytometry analysis, by selecting the DCs in peripheral blood mononuclear cells from healthy adults donors, was carried out.
a) Bacterial cultures and growth conditions
The strain was cultured in Man Rogosa Sharpe (MRS) medium, in a thermostatic bath at 37°C. As regards the immunomodulatory experiments, following to a growth period of approximately 16 hours, the bacteria were subcultured for 6 hours, under the above-cited conditions, in order to reach the exponential growth phase. Thus, they were washed twice with sterile phosphate-buffered saline (PBS, pH 7.2); the physiological status and the number of cells were determined with a cytofluorimetric technique by using the commercial kit "Cell Viability Kit with liquid beads", marketed by Becton Dickinson Company, following the manufacturer's instructions. The cells were then brought to the optimal concentration established in preliminary experiments and used in subsequent tests. b) Peripheral blood mononuclear cell separation
Peripheral blood mononuclear cells (PBMC) were separated by density gradient centrifugation. For this aim, 20 ml of "buffy coat" of healthy donors from the Immuno-transfusion Service of Ospedale di Borgomanero were used for each experiment, thereby obtaining an average yield of 200 x 106 PBMC/buffy. The amount of separated cells was determined by cell count in Burker's chambers, by using Turk's dye, which allows to discriminating between mononuclear cells and polymorphonuclear cells. The cells were brought to a concentration of 2 x 106 cells/ml in RPMI-1640 growth medium (Invitrogen), supplemented with 10% heat inactivated Bovine fetal serum (FCS, Gibco), 1% glutamine and 25 mM Hepes. c) PBMC stimulation
After separation, PBMCs were stimulated for 24 hours with the bacterial strain. The internal controls for each experiment were as follows: Negative control: PBMCs alone; 1 day control: PBMCs stimulated with 1 pg/ml Lipopolysaccharide (LPS; Escherichia coli, serotype 055.B5, Sigma Chemicals Co., St. Louis, MO).
After stimulation, the cultures were centrifuged at 1500 rpm for 10 minutes. Then the supernatant was discharged and the cells used for subsequent tests.
d) Total dendritic cells analysis
As regards the immunophenotypic characterization, cells were incubated for 30 minutes in the dark with different combinations of the following monoclonal antibodies (mAb) conjugated to fluorescein isothiocyanate (FITC) or peridinin chlorophyll protein (PerCP): CD3, CD14, CD16, CD19, CD20, CD56 and HLA-DR. After incubation, the samples were washed, fixed with a solution containing 1% paraformaldehyde and stored at 4°C. Within 24 hours from preparation, the samples were analyzed by a cytofluorimeter FACScalibur, the cells being selected so that to exclude contaminant cellular debris from analysis. e) Statistical analysis
A statistical analysis by using the paired Student's f test was performed. A p < 0.05 value was considered significant.
Results: Bacterial strain effect on dendritic cells
In order to determine the effect of the tested probiotic strain to the dendritic cell modulation, a multiparametric flow cytometric analysis was carried out.
As shown in figure 6A, after 24 hours, the stimulation with the strain LS 06 induced a significant increase of total dendritic cell (Lineage-/HLA-DR+) percentage.
Specifically, the bacterial strain L salivarius LS 06 (DSM 26037) increased by 7-fold the percentage of total dendritic cells, relative to non-stimulation conditions (baseline, figure 6B).
In figure 6B, the Mean ± S.E.M. of 12 independent experiments is shown. The statistical significance was calculated by using the Student's f test, p <0.05 values have to be considered statistically significant, as compared to the baseline (non-stimulated PBMCs).
In Table 2, the increase of dendritic cells induced by stimulation with different lactobacilli and bifidobacteria, relative to the baseline, is shown.
Conclusions
Data demonstrated that the bacterial strain L. salivarius LS 06 induced a significant increase of total DC percentage, relative to the standard basal conditions. In particular, the bacterium LS 06 increased by 7- fold the total DC percentage.
The intestinal colonization by bacteria capable to modulating the dendritic cells, such as the strain L. salivarius LS 06 being characterized in the present study, is a very important factor in diseases characterized by an immunological imbalance.
Table 1
27.42 ±
Bifidobacterium longum W11 wt 1161 None 4
6.78
29.09 ±
Bifidobacterium longum PCB133 1687 DSM 24691 4
8.25
14.94 +
Bifidobacterium longum BL05 1352 DS 23234 4
2.28
31.90 +
Bifidobacterium longum BL06 no ID DSM 24689 4
3.96
L. acidophilus LA02 1688 DSM 21717 8 4.91 ± 0.70
L. deldrueckii subsp.
LDD01 1391 DSM 22106 8 6.46 ±0.92 delbrueckii
L. fermentum LF09 1462 DSM 18298 8 0.80 ±0.15
L. fermentum LF10 1637 DSM 19187 8 4.25 ± 0.4
L plantarum LP01 1171 LMG P-21021 8 1.77 ± 0.42
L. plantarum LP02 91 LMG P-21020 8 4.59 ± 0.59
L. reuteri LRE02 1774 DSM 23878 4 1.19 ± 0.12
L. reuteri LRE04 1779 DSM 23880 4 1.72 ±0.39
L. reuteri DLLRE07 - DSM 25683 4 1.00 ± 0.07
L. reuteri DLLRE08 1841 DSM 25684 4 0.93 ± 0.06
L. reuteri DLLRE09 1842 DSM 25685 4 1.22 ± 0.29
L. rhamnosus LR06 1697 DSM 21981 10 2.64 ±0.83
L. salivarius LS01 1797 DSM 22775
10 1.44 ±0.13
L. salivarius LS04 - DSM 24618
L. salivarius LS03 1382 DSM 22776 10 0.72 ±0.26
L. salivarius DLV1 1806 DSM 25138 8 1.40 ±0.13
LS05
L. salivarius 1719 DSM 26036 4 1.80 ± 0.09
(L66)
L salivarius LS02 1468 DSM 20555 8 1.32 ±0.67
B. lactis BA05 1518 DSM 18352 8 1.24 ±0.08
B. breve BR03 1270 DSM 16604 10 2.20 ±0.20
B. breve BR03 1270 DSM 16604 8 6.92 ± 1.02
B. pseudolongum subsp.
BPS01 1812 None 8 0.64 ±0.33 globosum
B. longum B1975 1742 DSM 24709 4 2.99 ± 0.71
Table 2
Claims
1. A composition for use in antitumor chemotherapeutic treatments, acquired immunodeficiency syndrome treatments and leukemia treatments, said composition comprising a mixture consisting of:
- a strain of bacteria belonging to the species Lactobacillus reuteri identified as Lactobacillus reuteri LRE03 with deposit number DSM 23879, deposited on 05.08.2010 by Probiotical SpA at DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, and/or
- a strain of bacteria belonging to the species Lactobacillus salivarius identified as Lactobacillus salivarius LS06 with deposit number DSM 26037, deposited on 06.06.2012 by Probiotical SpA at DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
2. The composition for use according to claim 1 , wherein said composition comprises a mixture having a bacterial concentration comprised from 1x108 UFC/g of mixture to 1x1012 UFC/g of mixture, preferably from 1x109 UFC/g of mixture to 1x1011 UFC/g of mixture.
3. The composition for use according to claims 1 or 2, wherein said mixture comprises or, alternatively, consists of:
- a strain of bacteria Lactobacillus reuteri LRE03 DSM 23879 and a strain of bacteria Lactobacillus salivarius LS06 DSM 26037, in a weight ratio comprised from 1 :5 to 5:1 , preferably from 1 :3 to 3:1 , even more preferably from 1 :2 to 2:1 or 1 :1.
4. The composition for use according to any one of claims 1-3, wherein said composition further comprises an Aloe gel or a derivative thereof, preferably an Aloe arborescens gel; even more preferably it is a freeze- dried Aloe arborescens gel.
5. The composition for use according to any one of claims 1-4, wherein said composition contains freeze- dried Aloe arborescens in an amount comprised from 1 to 25% by weight, relative to the weight of the composition; preferably from 5 to 15% by weight, relative to the weight of the composition.
6. The composition for use according to any one of claims 1-5, wherein said composition further comprises a strain of bacteria belonging to the species Bifidobacterium lactis identified as Bifidobacterium lactis Bb 1 with deposit number DSM 17850, deposited at DSMZ on 23.12.2005, by BioMan S.r.l. Company, as tyndallized bacterial product, said strain being able to accumulate zinc inside the cells during its growth in a liquid culture medium.
7. The composition for use according to claim 6, wherein said tyndallized bacterial product of the strain Bifidobacterium animalis ssp. lactis Bb1 DSM 17850 is in an amount comprised from 10 to 50 mg/g of composition, preferably 20 mg/g of composition.
8. The composition for use according to any one of claims 1-7, wherein said composition further comprises one or more food grade or pharma grade excipients and/or additives and/or co-formulants being acceptable by the body, such as preferably fructooligosaccharides (FOS) and/or green tea and/or sucralose and/or maltodextrins.
9. The composition for use according to any one of claims 1-8, wherein said composition is for human and animal use as antitumor agent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20140816 | 2014-05-05 | ||
| PCT/IB2015/000602 WO2015170158A1 (en) | 2014-05-05 | 2015-04-30 | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3139940A1 true EP3139940A1 (en) | 2017-03-15 |
| EP3139940B1 EP3139940B1 (en) | 2021-02-17 |
Family
ID=51136602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP15736584.2A Active EP3139940B1 (en) | 2014-05-05 | 2015-04-30 | Composition comprising l. reuteri ler03 and l. salivarius ls06 for use in the treatment of tumors, aids and leukemias |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10413576B2 (en) |
| EP (1) | EP3139940B1 (en) |
| JP (1) | JP6804984B2 (en) |
| KR (1) | KR20160148651A (en) |
| CN (1) | CN107106629B (en) |
| CA (1) | CA2946463A1 (en) |
| DK (1) | DK3139940T3 (en) |
| RU (1) | RU2721565C2 (en) |
| WO (1) | WO2015170158A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6817070B2 (en) | 2014-05-05 | 2021-01-20 | キアラ・ベナッサイＣｈｉａｒａ ＢＥＮＡＳＳＡＩ | Adjuvant chemotherapeutic agents for tumors, acquired immunodeficiency syndrome and leukemia |
| JP6804984B2 (en) | 2014-05-05 | 2020-12-23 | キアラ・ベナッサイＣｈｉａｒａ ＢＥＮＡＳＳＡＩ | Therapeutic agents for use in the treatment of tumors, acquired immunodeficiency syndromes and leukemias with dual immune biostimulation |
| BR112019028301A2 (en) * | 2017-07-05 | 2020-07-14 | Evelo Biosciences, Inc. | compositions and methods for treating cancer using bifidobacterium animalis ssp. lactis |
| WO2019075452A1 (en) * | 2017-10-13 | 2019-04-18 | Evelo Biosciences, Inc. | Identification of bacteria for cancer therapy |
| CN116916942A (en) * | 2020-12-17 | 2023-10-20 | 欣巴伦斯有限公司 | Probiotic compositions and their use in the prevention and/or treatment of stress-related disorders |
| CN113215063B (en) * | 2021-06-16 | 2023-02-21 | 中国药科大学 | Lactobacillus salivarius and application thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2199305T3 (en) * | 1995-12-21 | 2004-02-16 | Biogaia Ab | USE OF LACTOBACILLUS REUTERI TO INHIBIT CRYPTOSPORIDIOSIS IN MAMMALS. |
| CN1370587A (en) * | 2002-03-05 | 2002-09-25 | 王舒妍 | Prepn of aloe gel |
| DK1567018T3 (en) * | 2002-10-18 | 2009-09-14 | Biogaia Ab | Method for Improving Immune Function in Mammals Using Lactobacillus Reuteri Strains |
| ITMI20051510A1 (en) * | 2005-08-02 | 2007-02-03 | Proge Farm Srl | USE OF SPECIFIC LACTIC BACTERIA FOR THE PREPARATION OF SINGLE-MODELING COMPOSITIONS |
| JP2007084533A (en) | 2005-08-24 | 2007-04-05 | Prima Meat Packers Ltd | Immune response-modulating composition and food with the same as active ingredient |
| ITTO20070555A1 (en) | 2007-07-26 | 2009-01-27 | Bioman S R L | BIOMASS ENRICHED IN ZINC, PROCEDURE FOR ITS PREPARATION AND PROBIOTIC, COSMETIC, DIETETIC AND NUTRACEUTICAL PRODUCTS INCLUDING THE BIOMASS |
| TWI346554B (en) | 2008-04-30 | 2011-08-11 | Genmont Biotech Inc | Lactobacillus isolates having anti-inflammatory activities and uses of the same |
| KR101001767B1 (en) | 2008-11-04 | 2010-12-15 | 주식회사한국야쿠르트 | Lactobacillus reuteri HY7501 having anti influenza viral effect and anti influenza viral composition containing thereof as an effective factor |
| WO2010077682A2 (en) | 2008-12-08 | 2010-07-08 | James Allen Lemke | Treatment of hiv and aids using probiotic lactobacillus reuteri |
| US20110117210A1 (en) * | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
| US20120107395A1 (en) * | 2010-11-01 | 2012-05-03 | Viva Pharmaceutical Inc. | Probiotic Soft Gel Compositions |
| CN102618452B (en) | 2011-02-01 | 2014-06-25 | 任发政 | Preparation method, composition and application of lactobacillus salivarius and its metabolites |
| ITMI20110679A1 (en) * | 2011-04-20 | 2012-10-21 | Giovanni Mogna | COMPOSITION INCLUDING PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF GASTRICITY. |
| ITRM20110477A1 (en) * | 2011-09-09 | 2013-03-10 | Giovanni Mogna | COMPOSITION INCLUDING N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTECT IN ASSOCIATION WITH PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF |
| KR20130048946A (en) | 2011-11-03 | 2013-05-13 | 가톨릭대학교 산학협력단 | Anti-cancer composition comprising lactobacillus reuteri cs132 or culture fluid of thereof |
| ITMI20120131A1 (en) | 2012-02-01 | 2013-08-02 | Probiotical Spa | MULTILAYER MICROCAPSULATED PROBIOTIC BACTERIA, THEIR PRODUCTION AND USE |
| JP6817070B2 (en) | 2014-05-05 | 2021-01-20 | キアラ・ベナッサイＣｈｉａｒａ ＢＥＮＡＳＳＡＩ | Adjuvant chemotherapeutic agents for tumors, acquired immunodeficiency syndrome and leukemia |
| JP6804984B2 (en) | 2014-05-05 | 2020-12-23 | キアラ・ベナッサイＣｈｉａｒａ ＢＥＮＡＳＳＡＩ | Therapeutic agents for use in the treatment of tumors, acquired immunodeficiency syndromes and leukemias with dual immune biostimulation |
-
2015
- 2015-04-30 JP JP2016566657A patent/JP6804984B2/en active Active
- 2015-04-30 CN CN201580023472.1A patent/CN107106629B/en not_active Expired - Fee Related
- 2015-04-30 KR KR1020167033185A patent/KR20160148651A/en not_active Application Discontinuation
- 2015-04-30 EP EP15736584.2A patent/EP3139940B1/en active Active
- 2015-04-30 US US15/307,756 patent/US10413576B2/en active Active
- 2015-04-30 DK DK15736584.2T patent/DK3139940T3/en active
- 2015-04-30 CA CA2946463A patent/CA2946463A1/en not_active Abandoned
- 2015-04-30 WO PCT/IB2015/000602 patent/WO2015170158A1/en active Application Filing
- 2015-04-30 RU RU2016143922A patent/RU2721565C2/en active
-
2019
- 2019-07-30 US US16/526,715 patent/US20190350989A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015170158A8 (en) | 2016-12-01 |
| CN107106629A (en) | 2017-08-29 |
| WO2015170158A1 (en) | 2015-11-12 |
| RU2721565C2 (en) | 2020-05-20 |
| US20170042951A1 (en) | 2017-02-16 |
| JP6804984B2 (en) | 2020-12-23 |
| RU2016143922A3 (en) | 2018-10-23 |
| EP3139940B1 (en) | 2021-02-17 |
| RU2016143922A (en) | 2018-06-05 |
| CN107106629B (en) | 2021-01-12 |
| US20190350989A1 (en) | 2019-11-21 |
| KR20160148651A (en) | 2016-12-26 |
| CA2946463A1 (en) | 2015-11-12 |
| JP2017514857A (en) | 2017-06-08 |
| DK3139940T3 (en) | 2021-05-17 |
| US10413576B2 (en) | 2019-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11077153B2 (en) | Composition for use in treating or preventing viral or bacterial infections in a subject undergoing anti-tumor chemotherapy, leukemia treatment or aids therapy comprising L. reuteri LER03 and/or L. salivarius LS06 | |
| US20190350989A1 (en) | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation | |
| DK2831287T3 (en) | COMPOSITION BASED ON STEMS OF BIFIDOBACTERIUM-LONGUM BACTERIA STANDING TO HELP EXTENDING LIFE | |
| Cross et al. | Dietary intake of Lactobacillus rhamnosus HN001 enhances production of both Th1 and Th2 cytokines in antigen-primed mice | |
| Aziz et al. | Activation of natural killer cells by probiotics | |
| Latvala et al. | Potentially probiotic bacteria induce efficient maturation but differential cytokine production in human monocyte-derived dendritic cells | |
| Lee et al. | Dead Lactobacillus plantarum stimulates and skews immune responses toward T helper 1 and 17 polarizations in RAW 264.7 cells and mouse splenocytes | |
| KR20110125667A (en) | Bacteria strains having a high anti-inflammatory activity | |
| Hsieh et al. | Potential of probiotic strains to modulate the inflammatory responses of epithelial and immune cells in vitro | |
| ES2331863B1 (en) | BACTERIA AND DERIVATIVE PRODUCTS TO STRENGTHEN DEFENSES AND REDUCE THE RISK OF DISEASE. | |
| Rolny et al. | Lactobacillus delbrueckii subsp lactis CIDCA 133 modulates response of human epithelial and dendritic cells infected with Bacillus cereus. | |
| Ongol et al. | Potential of selected strains of lactic acid bacteria to induce a Th1 immune profile | |
| Masuda et al. | TLR ligands of Lactobacillus sakei LK-117 isolated from seed mash for brewing sake are potent inducers of IL-12 | |
| RU2674658C2 (en) | Composition for application as supporting therapy for treatment of tumours, acquired immunodeficiency syndrome and leukemia | |
| CN114634884B (en) | Bifidobacterium longum subspecies GB-1496 and application thereof in improving intestinal bacterial infection resistance and intestinal immunity | |
| Lee et al. | Effect of Bifidobacterium cell fractions on IL-6 production in RAW 264.7 macrophage cells | |
| Hagigi et al. | Evaluation the effects of heated TC1 extract in combination with Lactobacillus Casei extract and alpha-galactosyl ceramide on mouse model of cervical cancer caused by the papilloma virus | |
| Soria et al. | Disruption of lipid rafts enhances the effect of lactobacilli on the production of tumor necrosis factor-alpha in mononuclear blood cells | |
| CN118805902A (en) | Breast milk oligosaccharide | |
| Підгорський et al. | EFFECTS OF DRY ENZYMATIC LYSATE DEL-IMMUNE V® ON CYTOKINE PRODUCTION IN THE EXPERIMENTAL MODELS | |
| ITRM20130174A1 (en) | STRAIN OF LACTOBACILLUS AND ITS USE AS A PROBIOTIC | |
| Pidgorskyi et al. | EFFECTS OF DRY ENZYMATIC LYSATE DEL-IMMUNE V® ON CYTOKINE PRODUCTION IN THE EXPERIMENTAL MODELS | |
| Frøkiær | Louise Hjerrild Zeuthen, Hanne Risager Christensen and |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20161124 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PROBIOTICAL S.P.A. |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20180424 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602015065591 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0035740000 Ipc: A61K0035747000 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20200825BHEP Ipc: A61K 35/747 20150101AFI20200825BHEP Ipc: A61P 31/18 20060101ALI20200825BHEP Ipc: A61P 35/02 20060101ALI20200825BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20200916 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015065591 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1360574 Country of ref document: AT Kind code of ref document: T Effective date: 20210315 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210512 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210517 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210517 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210518 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210617 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1360574 Country of ref document: AT Kind code of ref document: T Effective date: 20210217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210617 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015065591 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210430 |
|
| 26N | No opposition filed |
Effective date: 20211118 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210617 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220427 Year of fee payment: 8 Ref country code: DE Payment date: 20220502 Year of fee payment: 8 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602015065591 Country of ref document: DE Representative=s name: FRANKE & PARTNER PATENT- UND RECHTSANWAELTE IN, DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20150430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230427 Year of fee payment: 9 Ref country code: FR Payment date: 20230419 Year of fee payment: 9 Ref country code: DK Payment date: 20230418 Year of fee payment: 9 Ref country code: CH Payment date: 20230502 Year of fee payment: 9 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602015065591 Country of ref document: DE |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231103 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210217 |